Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 3, 2011, Pages 521-532

  Sun, Qiang Ling ^a   Sha, Hui Fang ^a   Yang, Xiao Hua ^a   Bao, Guo Liang ^a   Lu, Jing ^a   Xie, Yin Yin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Chemoresistance; Non Small Cell Lung Cancer (NSCLC); Paclitaxel; Two dimensional difference gel electrophoresis (2D DIGE)

Indexed keywords

ANNEXIN; ANNEXIN 1; CALPASTATIN; CISPLATIN; CYTOKERATIN 18; CYTOKERATIN 8; GEMCITABINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; RETINAL DEHYDROGENASE; RETINAL DEHYDROGENASE 1; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN A549; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; CYTOSKELETON; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; ENERGY METABOLISM; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MITOCHONDRION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; UPREGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PACLITAXEL; PEPTIDE MAPPING; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79954432202     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0913-9     Document Type: Article

References (36)

1. Bergman PJ (2003) Mechanisms of anticancer drug resistance. Vet Clin North Am Small Anim Pract 33:651-667 (Pubitemid 36798642)
2. Board P, Harris M, Flanagan J, Langton L, Coggan M (1998) Genetic heterogeneity of the structure and function of GSTT2 and GSTP1. Chem Biol Interact 111-112:83-89 (Pubitemid 28271936)
3. Canuto RA, Ferro M, Muzio G, Bassi AM, Leonarduzzi G, Maggiora M, Adamo D, Poli G, Lindahl R (1994) Role of aldehyde metabolizing enzymes in mediating effects of aldehyde products of lipid peroxidation in liver cells. Carcinogenesis 15:1359-1364 (Pubitemid 24217687)
4. Caulin C, Ware CF, Magin TM, Oshima RG (2000) Keratindependent, epithelial resistance to tumor necrosis factor-induced apoptosis. J Cell Biol 149:17-22 (Pubitemid 30196695)
5. Emori Y, Imajoh-Ohmi S, Maki M (1992) Calpain and calpastatin-structure and function. Seikagaku 64:1201-1224
6. Fais S, De Milito A, Lozupone F (2005) The role of FAS to ezrin association in FAS-mediated apoptosis. Apoptosis 10:941-947 (Pubitemid 41285573)
7. Gautreau A, Poullet P, Louvard D, Arpin M (1999) Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96:7300-7305 (Pubitemid 29299656)
8. Gervasoni JE Jr, Hindenburg AA, Vezeridis MP, Schulze S, Wanebo HJ, Mehta S (2004) An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Anticancer Res 24:2617-2626 (Pubitemid 39407135)
9. Gilbert S, Loranger A, Daigle N, Marceau N (2001) Simple epithelium keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J Cell Biol 154:763-773 (Pubitemid 34292958)
10. Gomperts BN, Gong-Cooper X, Hackett BP (2004) Foxj1 regulates basal body anchoring to the cytoskeleton of ciliated pulmonary epithelial cells. J Cell Sci 117:1329-1337 (Pubitemid 38559811)
11. Gonzalez-Santiago L, Alfonso P, Suarez Y, Nunez A, Garcia-Fernandez LF, Alvarez E, Munoz A, Casal JI (2007) Proteomic analysis of the resistance to aplidin in human cancer cells. J Proteome Res 6:1286-1294 (Pubitemid 46724025)
12. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB (1995) Altered expression of M beta 2, the class II betatubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270:31269-31275
13. Impens F, Van Damme P, Demol H, Van Damme J, Vandekerckhove J, Gevaert K (2008) Mechanistic insight into taxol-induced cell death. Oncogene 27:4580-4591
14. Inada H, Izawa I, Nishizawa M, Fujita E, Kiyono T, Takahashi T, Momoi T, Inagaki M (2001) Keratin attenuates tumor necrosis factor-induced cytotoxicity through association with TRADD. J Cell Biol 155:415-426
15. Ishii T, Teramoto S, Matsuse T (2004) GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells. Cancer Lett 216:89-102 (Pubitemid 39410500)
16. Jaffrezou JP, Dumontet C, Derry WB, Duran G, Chen G, Tsuchiya E, Wilson L, Jordan MA, Sikic BI (1995) Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res 7:517-527 (Pubitemid 26075385)
17. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30 (Pubitemid 40310185)
18. Le Moguen K, Lincet H, Deslandes E, Hubert-Roux M, Lange C, Poulain L, Gauduchon P, Baudin B (2006) Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics 6:5183-5192 (Pubitemid 44549991)
19. Li L, Luan Y, Wang G, Tang B, Li D, Zhang W et al (2004) Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. Int J Mol Med 14:257-264
20. Lilley KS (2003) Protein profiling using two-dimensional difference gel electrophoresis (2-D DIGE). Curr Protoc Protein Sci Chapter 22: Unit 22 22
21. Liu Y, Liu H, Han B, Zhang JT (2006) Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66:3248-3255
22. Luciani F, Molinari A, Lozupone F, Calcabrini A, Lugini L, Stringaro A, Puddu P, Arancia G, Cianfriglia M, Fais S (2002) P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood 99:641-648 (Pubitemid 34533103)
23. Murachi T (1990) Calpain and calpastatin. Rinsho Byori 38:337-346
24. Murphy L, Henry M, Meleady P, Clynes M, Keenan J (2008) Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line. Biochim Biophys Acta 1784:1184-1191
25. Parekh H, Simpkins H (1997) The transport and binding of taxol. Gen Pharmacol 29:167-172 (Pubitemid 27312365)
26. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004-1014
27. Sakai T (2006) Drug resistance and cell survival mechanisms for anticancer drugs. Nippon Yakurigaku Zasshi 127:342-347 (Pubitemid 351420576)
28. Sangrajrang S, Fellous A (2000) Taxol resistance. Chemotherapy 46:327-334
29. Seve P, Dumontet C (2005) Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 5:73-88 (Pubitemid 40081296)
30. Timms JF, Cramer R (2008) Difference gel electrophoresis. Proteomics 8:4886-4897
31. Tsukita S, Yonemura S (1997) ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol 9:70-75 (Pubitemid 27065111)
32. Wang YF, Chen CY, Chung SF, Chiou YH, Lo HR (2004) Involvement of oxidative stress and caspase activation in paclitaxel-induced apoptosis of primary effusion lymphoma cells. Cancer Chemother Pharmacol 54:322-330
33. Wendt A, Thompson VF, Goll DE (2004) Interaction of calpastatin with calpain: a review. Biol Chem 385:465-472 (Pubitemid 38967773)
34. Wilson TR, Longley DB, Johnston PG (2006) Chemoresistance in solid tumours. Ann Oncol 17 (Suppl 10): x315-x324 (Pubitemid 44542029)
35. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1-19 (Pubitemid 36119417)
36. Zhang JT, Liu Y (2007) Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat Rev 33:741-756 (Pubitemid 350082667)